4.7 Article

Beneficial Effects of Treatment With Anti-IgE Antibodies (Omalizumab) in a Patient With Severe Asthma and Negative Skin-Prick Test Results

期刊

CHEST
卷 139, 期 1, 页码 190-193

出版社

ELSEVIER SCIENCE BV
DOI: 10.1378/chest.10-0128

关键词

-

资金

  1. GlaxoSmithKline (GSK)
  2. AstraZeneca
  3. Nycomed
  4. Dutch Asthma Foundation
  5. Zorg Onderzoek Nederland Medische Wetenschappen

向作者/读者索取更多资源

It is now well recognized that treatment with anti-IgE antibodies like omalizumab is a valuable option in patients with allergic asthma who remain symptomatic despite optimal treatment. To our knowledge, treatment with omalizumab in patients with nonallergic asthma has not been reported. We present and discuss a patient with severe asthma and elevated total IgE who had a negative radioallergosorbent (RAST) test result and a negative skin-prick test result; the patient showed a dramatic improvement with this treatment strategy. CHEST 2011; 139(1):190-193

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据